Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 3/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL471054 | 0.91 | PDE9A (0.37) | PDE9ACYP11B2SSTR4SPR | |
| SCHEMBL15103307 | 0.89 | PDE9A (0.35) | PDE9A | |
| SCHEMBL15103278 | 0.89 | PDE9A (0.35) | PDE9A | |
| SCHEMBL15103266 | 0.88 | NOTUM (0.40) | PDE9ACYP2C9 | |
| SCHEMBL15103227 | 0.83 | CYP11B2 (0.34) | PDE9ACYP11B2SSTR4SPR | |
| SCHEMBL15103353 | 0.83 | CYP11B2 (0.35) | CYP11B2SSTR4SPRSMN1; SMN2 | |
| SCHEMBL7908729 | 0.81 | PDE9A (0.38) | PDE9ACYP11B2 | |
| SCHEMBL15103355 | 0.81 | PDE9A (0.47) | PDE9A | |
| SCHEMBL7913632 | 0.80 | PDE9A (0.39) | PDE9ACYP11B2 | |
| SCHEMBL7907820 | 0.80 | PDE9A (0.33) | PDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901126-B2 | Substituted imidazo[1,5-A]quinoxalin-4-ones are useful for preventing or treating storage dysfunction, voiding dysfunction and bladder/urethral diseases | ASTELLAS PHARMA INC. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901126-B2 | Substituted imidazo[1,5-A]quinoxalin-4-ones are useful for preventing or treating storage dysfunction, voiding dysfunction and bladder/urethral diseases | ASTELLAS PHARMA INC. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901126-B2 | Substituted imidazo[1,5-A]quinoxalin-4-ones are useful for preventing or treating storage dysfunction, voiding dysfunction and bladder/urethral diseases | ASTELLAS PHARMA INC. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20130296329-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296329-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296329-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| EP-2615096-A1 | QUINOXALINE COMPOUND | Astellas Pharma Inc. (JP) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012033101-A1 | QUINOXALINE COMPOUND | アステラス製薬株式会社 (JP) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296329-A1 | QUINOXALINE COMPOUND | PDE9A, PDE5A, PDE2A | PDE9A 1/4885CYP11B2 3623/4885SSTR4 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.